Research reports san francisco 2012

Friday, April 20, 2012 Moscone West Convention Center Exhibit Hall, Level I Descriptive Research Reports describe new, improved or innovative roles or services in managed care pharmacy practice that are of such importance that they should be brought to the attention of other pharmacy professionals. The following posters were selected for presentation: PRR-01: The Effect of Cost-Sharing on Patients Likelihood of Receiving Disease Modifying Therapies for Multiple Sclerosis Safiya Abouzaid, PharmD, Assistant Director, Novartis Pharmaceuticals Corporation PRR-02: Comparison of Different Measures to Calculate Adherence with Fingolimod Safiya Abouzaid, PharmD, Assistant Director, Novartis Pharmaceuticals Corporation PRR-03: Effect of Medicare Part D Coverage on Adherence with Disease Modifying Drug Therapy for Multiple Sclerosis Benjamin Banahan, PhD, Director and Research Professor, University of Mississippi, Center for Pharmaceutical Marketing and Management PRR-04: An Empirical Approach to Measure and Predict Treatment Persistence Among Insulin Glargine Treated Patients with Type 2 Diabetes Lin Xie, MS, Director, Health Economics and Outcomes Research, STATinMED Research PRR-05: Advantages of an Integrated System in Changing Proton Pump Inhibitor Prescribing Patterns Michelle Beozzo, PharmD, Clinical Pharmacist Medication Use Management, Denver Health Medical Plan, Inc. PRR-06: Dosing Patterns of Infliximab in Rheumatoid Arthritis Patients Enrolled in a Mid-Atlantic Commercial Health Plan Susan Bolge, PhD, Associate Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-07: Reasons for Discontinuation of Subcutaneous Biologic Therapy in the Treatment of Rheumatoid Arthritis: A Patient Perspective Susan Bolge, PhD, Associate Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-08: Time to Disease Modifying Antirheumatic Drug Initiation Among Newly Diagnosed Rheumatoid Arthritis Patients Machaon Bonafede, PhD, MPH, Lead Researcher, Thomson Reuters PRR-09: Employees Living with Human Immunodeficiency Virus: Impact of Disease and Antiretroviral Therapies on Healthcare Costs and Productivity Richard Brook, MS, MBA, Head, Retrospective Analysis, The JeSTARx Group PRR-10: The Economic Implications of New Onset Depression in Newly Diagnosed Multiple Sclerosis Patients-Implications for Managed Care Pharmacy Practice Cathryn Carroll, PhD, MA, MBA, BSPharmacy, Associate Professor, Health Economics an Outcomes Research, Teva Pharmaceutical Ind. Ltd. PRR-11: Synergistic Effects of Personalized Pharmacist Counseling and Pharmacy Benefit Design on Patients with Suboptimal Therapeutic Management of Diabetes Andrew Chang, MPH, Research Advisor, CVS Caremark PRR-12: Outcomes After Initiation of Fluticasone Propionate-Salmeterol Combination Versus Anti-Cholinergics in Patients with Moderate Exacerbations of COPD Anand Dalal, PhD, MBA, Director, U.S. Health Outcomes, GlaxoSmithKline PRR-13: Anticoagulants for Stroke Prophylaxis in a Commercially Insured Atrial Fibrillation Population Dilesh Doshi, PharmD, Director, Janssen Scientific Affairs, LLC PRR-14: Communication Intervention for Influencing Physician Prescribing Behavior Paul DuBose, PhD, Vice President Analytics, Principled Strategies, Inc. PRR-15: Community Pharmacy: A Preferred Channel to Fill 90-Day Prescriptions for Chronic Medications Janeen DuChane, PhD, Senior Director, Outcomes and Analytics, Walgreens Co. PRR-16: Use of Health Economic and Outcomes Research in Formulary Decision Making: A Tale of Two Surveys Joseph Dye, RPh, PhD, Assistant Professor and Director, Mercer University College of Pharmacy and Health Sciences PRR-17: The Association Between Use of Mealtime Insulin Pens Versus Vials and Healthcare Charges in Patients with Type 2 Diabetes Elizabeth Eby, MPH, Research Scientist, Global Health Outcomes, Lilly USA, LLC PRR-18: Outcomes Associated with Use of Mealtime Insulin Pens Versus Vials in Patients with Type 2 Diabetes Elizabeth Eby, MPH, Research Scientist, Global Health Outcomes, Lilly USA, LLC PRR-19: Impact of a Dalfampridine (Ampyra) Prior Authorization Edit Beckie Fenrick, PharmD, MBA, Senior Director, Clinical Pharmacy, BlueCross BlueShield of Florida PRR-20: Utilization of Anticoagulation Therapy in Medicare 5% Sample Claim Data for Patients with Nonvalvular Atrial Fibrillation: Comparison to Clinical Guideline Recommendations Kate Fitch, RN, MEd, Principal and Healthcare Consultant, Milliman, Inc. PRR-21: Hypertension Medication Adherence Association with Hospitalizations and Total Cost of Care Patrick Gleason, PharmD, FCCP, BCBS, Director of Clinical Outcomes Assessment, Prime Therapeutics, LLC PRR-22: Integrated Medical and Pharmacy Prevalence of Members Diagnosed and Treated Within a Specialty Condition/Drug Class Patrick Gleason, PharmD, FCCP, BCBS, Director of Clinical Outcomes Assessment, Prime Therapeutics, LLC PRR-23: The Economic Burden of Treatment Failure in Medicaid Patients with Irritable Bowel Syndrome with Constipation Annie Guerin, MSc, Senior Economist, Analysis Group Inc. PRR-24: The Impact of Biologics on the Burden of Rheumatoid Arthritis Candace Gunnarsson, EdD, MA, President and Chief Executive Officer, S2 Statistical Solutions, Inc. PRR-25: Utilization of Mathematical Modeling to Determine Possible Cost Savings and Cost Avoidance for Implementation of MTM Services in a Specialty Population Christopher Holtzer, PharmD, Manager, Clinical Services, Ramsell Pharmacy Solutions PRR-26: Factors Associated with Unclaimed Prescriptions in the Electronic Prescription Era Rita Hui, PharmD, MS, Outcomes Research Pharmacist, Kaiser Permanente PRR-27: Recent Trends in the Prevalence of HCV-Infected Medicare Patients and the Associated Cost Burden Martin Zalesak, MD, PhD, Senior Consultant, Trinity Partners, LLC PRR-28: Patterns of Response to TNF Inhibitors by Mode of Administration from the CORRONA Registry: Implications for Treat to Target Strategies Michael Ingham, MSc Epidemiology, Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-29: Number Needed to Treat, Cost per Responder and Budget Impact of Long-Standing Tumor Necrosis Factor-Inhibitors in Psoriatic Arthritis Michael Ingham, MSc Epidemiology, Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-30: Calculation of Annual Biologic Treatment Costs in Rheumatoid Arthritis: A Comparison of Methods and Relationship to Adherence Michael Ingham, MSc Epidemiology, Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-31: The Use of Propensity Scores to Control for Baseline Characteristics in a Comparison of Healthcare Utilization Donald Klepser, PhD, MBA, Assistant Professor, University of Nebraska Medical Center PRR-32: Compliance with Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Recurrent Events Joyce LaMori, MHS, MBA, Associate Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-33: Prescription Savings Club Membership Drives Medication Adherence Robert London, PhD, National Medical Director, Walgreens Co. PRR-34: Evaluation of Right Heart Catheterization Results for Members Prescribed Pulmonary Arterial Hypertension Medication Erin Lopata, PharmD, Clinical Pharmacy Specialist, UPMC Health Plan PRR-35: The Impact of Consumer Driven Health Plans on Member Decisions Daniel Loos, Senior Analyst, CVS Caremark PRR-36: Observed Dosing Patterns for Ustekinumab in the Treatment of Moderate-to-Severe Psoriasis: Evaluation of Data from 14 Commercial Health Plans Silas Martin, MS, Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC PRR-37: The High-Cost Type 2 Diabetes Mellitus Patient: Findings from a United States Managed Care Population Juliana Meyers, MA, Associate Director, Health Economics, RTI Health Solutions PRR-38: Effect of Daily Antiretroviral Pill Burden on Hospitalizations in United States Medicaid Enrollees with HIV: An Analysis of Hospital Characteristics and Costs Juliana Meyers, MA, Associate Director, Health Economics, RTI Health Solutions PRR-39: Increasing the Intensity of Interventions Improves Resolution of Drug Related Problems in a Medication Therapy Management Program Cathrine Misquitta, PharmD, BCPS, Director, Clinical Pharmacy Services, Health Net Inc. PRR-40: Impact of Community Pharmacist-Led Counseling on Patient Medication Adherence Jenny Jiang, MS, Senior Health Outcomes Analyst, Walgreens Co. PRR-41: Impact of HIV-Specialized Pharmacies on Adherence to Antiretroviral Therapy Patricia Murphy, MPH, Senior Analyst, Walgreens Co. PRR-42: Poor Symptom Control with Short-Acting Inhaled Medications in Nursing Home Residents with COPD Terry O'Shea, PharmD, CGP, FASCP, Senior Clinical Director of Consultant Performance, Omnicare, Inc. PRR-43: Adherence and Medical Cost Patterns of Treatment with RAS Inhibitor/Amlodipine Combinations Sumeet Panjabi, PhD, Associate Director, Daiichi Sankyo Inc. PRR-44: Drug Characteristics Associated with Medication Adherence Across Eight Disease States Pamala Pawloski, PharmD, Research Investigator, HealthPartners PRR-45: Risk Factors Associated with Non-Adherence of Disease-Modifying Drugs Among Patients with Multiple Sclerosis Amy Phillips, PharmD, Associate Director, Health Outcomes and Market Access, EMD Serono, Inc. PRR-46: Repository Corticotropin Injection (H.P. Acthar Gel): Cost Analysis and Utilization Management Opportunity Assessment Jill Phillips, RPh, Senior Clinical Pharmacist, Prime Therapeutics, LLC PRR-47: Filgrastim (Neupogen) and Pegfilgrastim (Neulasta): Cost Analysis and Utilization Management Opportunity Assessment Jill Phillips, RPh, Senior Clinical Pharmacist, Prime Therapeutics, LLC PRR-48: Consumer Directed Health Plans (CDHP) – Impact on Member Adherence to Chronic Condition Medications Shalini Prakash, BSPharmacy, MS, Advisor, Analytic Consulting Services, CVS Caremark PRR-49: The Association Between Adherence to Oral Bisphosphonate Osteoporosis Medications, Fracture Rates and Expenditures Karim Prasla, PharmD, MS, Assistant Director, Health Economics and Outcomes Research, Scott & White PRR-50: Results of an Antidepressant Step-Therapy Reject Mitigation Project – Physician Intervention Shannon Redline, PharmD, Clinical Pharmacist, Health Net Inc. PRR-51: Characteristics of Rheumatoid Arthritis Patients who Initiate Anti-TNF Therapy and Switch to Abatacept or a Second Anti-TNF Agent Lisa Rosenblatt, MD, MPH, Associate Director, Health Services, Bristol-Myers Squibb PRR-52: Evaluation of a Pharmacist-Led Medication Reconciliation Program in Post-Discharge Patients: A Phase II Study Sheila Salamunovich, PharmD, Manager, Pharmacy Services, HealthCare Partners PRR-53: Presence of Comorbid Diseases and Use of Concomitant Drugs that are Contraindicated or Could Potentially Complicate Treatment when Used with Gout Drugs in Patients with Frequent Gouty Arthritis Attacks Joseph Saseen, PharmD, BCPS, Professor, Clinical Pharmacy and Family Medicine, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences PRR-54: Impact of a Tier Reduction on Statin Adherence Sonali Shah, RPh, MBA, MPH, Director, Health Economics and Outcomes Research, Pfizer Inc. PRR-55: Disease-Specific Costs and Resource Utilization Associated with the Initiation of Insulin Therapy Within a Type 2 Diabetes Mellitus Population Manan Shah, PharmD, PhD, Director, Xcenda PRR-56: Cost-Effectiveness of Select First-line Chemotherapy Regimens in the Treatment of Nonsquamous Non-Small Cell Lung Cancer Patients in the Outpatient Setting Manan Shah, PharmD, PhD, Director, Xcenda PRR-57: Atypical Antipsychotics Versus Non-Antipsychotics: Comparative Treatment Patterns, Resource Utilization and Costs in Stimulant-Treated Adolescents with ADHD who Require Subsequent Pharmacotherapy Vanja Sikirica, PharmD, MPH, Director, Global Health Economics and Outcomes Research, Shire PRR-58: Warfarin Pharmacogenomics Testing: Prevalence, Timeliness and Cost Catherine Starner, PharmD, BCPS, CGP, Senior Clinical Pharmacist, Prime Therapeutics, LLC PRR-59: Health Resource Utilization and Costs Associated with the Infusion and Monitoring of Zoledronic Acid in Female Health Plan Members with Osteoporosis Bradley Stolshek, PharmD, Director, Global Health Economics, Amgen Inc. PRR-60: Association Between Osteoporosis (OP) and Total Health Care Costs in Members with High Cost Chronic Diseases in a Managed Care Setting Sarah Thayer, MA, Senior Researcher, Health and Economics Outcomes, OptumInsight PRR-61: Resolving Therapeutic Care Gaps in Community Pharmacies: The Illinois Project Daniel Touchette, PharmD, MA, Associate Professor, University of Illinois at Chicago, College of Pharmacy PRR-62: Comorbidity and Cost Burden of Patients Prior to Initiating First-Line Biologic Therapy for the Treatment of Rheumatoid Arthritis Digisha Trivedi, PhD, Associate Director, Health Services, Bristol-Myers Squibb PRR-63: Managing Specialty Medication Services Through a Specialty Pharmacy Program: The Case of Oral Renal Transplant Immunosuppressant Medications Suzanne Tschida, PharmD, BCPS, Vice President, Specialty Benefit and Outcomes Strategy, OptumRx PRR-64: Impact of Utilization Management Strategies for Febuxostat on the Use of Chronic Gout Therapy Sharon Wang, PharmD, MS, Senior Health Outcomes Researcher, MedImpact Healthcare Systems, Inc. PRR-65: Real-World Outcomes of Switching from Vial/Syringe to Disposable Pen Among Elderly Patients with Type 2 Diabetes Mellitus who were Treated with Insulin Glargine Wenhui Wei, PhD, MS, Director Evidence Based Medicine Research, Sanofi US PRR-66: Cost and Utilization Outcomes of Opioid Dependence Treatments Andrew Weis, PharmD, Medical Science Liaison, Alkermes Inc. PRR-67: The Role of Patient Reported Outcomes in the Payer Evidence Evaluation Process Nathan White, CPC, Executive Director, Access and Reimbursement, inVentiv Health Inc. PRR-68: Identifying Risk Factors Associated with Nonadherence to Medication in Patients with Ulcerative Colitis Linnette Yen, MS, MA, Director, Global Health Economics and Outcomes Research, Shire

Source: http://www.amcpmeetings.org/past/2012spring/PDF/PRR.pdf